Patents by Inventor Francois Valette

Francois Valette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating and prognosing cancer
    Patent number: 11723948
    Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: August 15, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), NANTES UNIVERSITÈ, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre-Francois Cartron, Mathilde Cheray, Francois Valette
  • METHOD FOR TREATING AND PROGNOSING CANCER
    Publication number: 20200282011
    Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: Pierre-Francois CARTRON, Mathilde CHERAY, Francois VALETTE
  • Method for treating and prognosing cancer
    Patent number: 10697965
    Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 30, 2020
    Assignees: INSERM (INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre-Francois Cartron, Mathilde Cheray, Francois Valette
  • NEW METHOD FOR TREATING AND PROGNOSING CANCER
    Publication number: 20180238885
    Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
    Type: Application
    Filed: March 1, 2016
    Publication date: August 23, 2018
    Inventors: Pierre-Francois CARTRON, Mathilde CHERAY, Francois VALETTE
  • Installation for storing and recovering heat energy, particularly for a solar power station
    Patent number: 4262735
    Abstract: An installation for storing and recovering heat energy having a principal application in solar power stations.The heat produced is stored in a storage reservoir when the converted energy demanded is less than the heat energy produced, and recovered in the opposite case, these operations being carried out entirely automatically. The heat transfers are effected through a thermofluid able to flow by streaming over containers of any shape, enclosing a heat storage substance, and disposed loosely or methodically in said storage reservoir.
    Type: Grant
    Filed: June 8, 1978
    Date of Patent: April 21, 1981
    Assignee: Agence Nationale de Valorisation de la Recherche
    Inventors: Philippe Courrege, Jean Deflandre, Francois Valette